Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To assess if percentage change in 18F-FLT PET/CT quantitative parameters (SUV max, or SUV
peak or proliferative tumor volume) after 2 cycles of neoadjuvant chemotherapy can predict
overall survival at 1 and 2 years and progression free survival at 6 months and 1 year in
patients with borderline resectable or locally advanced, pancreatic adenocarcinoma.